MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
Language English Country Slovakia Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Dacarbazine analogs & derivatives therapeutic use MeSH
- DNA Modification Methylases genetics MeSH
- Adult MeSH
- DNA Repair Enzymes genetics MeSH
- Glioblastoma genetics therapy MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- DNA Methylation MeSH
- MicroRNAs analysis MeSH
- Biomarkers, Tumor MeSH
- Tumor Suppressor Proteins genetics MeSH
- Brain Neoplasms genetics therapy MeSH
- Promoter Regions, Genetic MeSH
- Aged MeSH
- Temozolomide MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Dacarbazine MeSH
- DNA Modification Methylases MeSH
- DNA Repair Enzymes MeSH
- MGMT protein, human MeSH Browser
- MicroRNAs MeSH
- MIrn181 microRNA, human MeSH Browser
- Biomarkers, Tumor MeSH
- Tumor Suppressor Proteins MeSH
- Temozolomide MeSH
MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies showed altered expression levels of several microRNAs in glioblastomas. In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas. MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0.016), miR-222 (p=0.038), miR-181b (p=0.036), miR-181c (p=0.043) and miR-128a (p=0.001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p<0.001). MiR-181b and miR-181c were significantly down-regulated in patients who responded to RT/TMZ (p=0.016; p=0.047, respectively) in comparison to patients with progredient disease. Our data indicate for the first time that expression levels of miR-181b and miR-181c could serve as a predictive marker of response to RT/TMZ therapy in glioblastoma patients.
References provided by Crossref.org
MicroRNAs involved in chemo- and radioresistance of high-grade gliomas
Novel classes of non-coding RNAs and cancer
Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer
MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications
